New combo aims to tackle tough uterine cancer
NCT ID NCT05559879
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs, cabozantinib and dostarlimab, in 37 women with recurrent gynecologic carcinosarcoma, a rare and aggressive cancer. The goal is to see if the combo can keep the cancer from growing for at least 6 months. Participants must have had at least one prior chemotherapy and have measurable tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib and dostarlimab
What this could lead to
If it works, this combination could offer a new treatment option for women with recurrent gynecologic carcinosarcoma, potentially slowing cancer growth.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply broadly. The combination may cause side effects and might not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
O'Neal Comprehensive Cancer Center at UAB
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Email: •••••@•••••
Contact
Contact